Ken Griffin Inmune Bio, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 21,400 shares of INMB stock, worth $188,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,400

Previous 8,800 143.18%

Holding current value

$188,748

Previous $99,000 153.54%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.53 - $14.01 $356,135 - $473,832	-33,821 Reduced 99.91%	30 $0
Q4 2023 Feb 14, 2024	BUY	$6.6 - $11.52 $129,333 - $225,745	19,596 Added 137.47%	33,851 $381,000
Q3 2023 Nov 14, 2023	SELL	$6.61 - $10.9 $169,116 - $278,876	-25,585 Reduced 64.22%	14,255 $96,000
Q2 2023 Aug 14, 2023	BUY	$6.5 - $10.09 $7,345 - $11,401	1,130 Added 2.92%	39,840 $361,000
Q1 2023 May 15, 2023	SELL	$6.01 - $10.18 $19,929 - $33,756	-3,316 Reduced 7.89%	38,710 $250,000

Q4 2022 Feb 14, 2023	BUY	$6.31 - $7.96 $100,291 - $126,516	15,894 Added 60.82%	42,026 $266,000
Q3 2022 Nov 14, 2022	BUY	$6.91 - $10.44 $65,430 - $98,856	9,469 Added 56.83%	26,132 $162,000
Q2 2022 Aug 15, 2022	SELL	$5.48 - $8.97 $53,720 - $87,932	-9,803 Reduced 37.04%	16,663 $147,000
Q1 2022 May 16, 2022	SELL	$6.42 - $11.39 $265,961 - $471,853	-41,427 Reduced 61.02%	26,466 $223,000
Q4 2021 Feb 14, 2022	BUY	$9.97 - $20.38 $151,553 - $309,796	15,201 Added 28.85%	67,893 $692,000
Q3 2021 Nov 15, 2021	SELL	$14.13 - $27.85 $47,533 - $93,687	-3,364 Reduced 6.0%	52,692 $1.02 Million
Q2 2021 Aug 16, 2021	BUY	$9.29 - $19.33 $520,760 - $1.08 Million	56,056 New	56,056 $984,000
Q2 2019 Aug 14, 2019	SELL	$7.45 - $11.0 $75,922 - $112,101	-10,191 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.08 - $8.2 $72,152 - $83,566	10,191 New	10,191 $0

Others Institutions Holding INMB

# of Institutions

Shares Held

2.88M

Call Options Held

44.6K

Put Options Held

3.5K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $158M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account